China Biologic Products Holdings Inc (NASDAQ:CBPO) has been assigned an average recommendation of “Hold” from the eight ratings firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $94.50.
Several equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of China Biologic Products from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 9th. Credit Suisse Group downgraded shares of China Biologic Products from an “outperform” rating to a “neutral” rating in a research note on Monday, August 6th. BidaskClub downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Saturday, August 18th. ValuEngine upgraded shares of China Biologic Products from a “sell” rating to a “hold” rating in a research note on Thursday, November 1st. Finally, Morgan Stanley downgraded shares of China Biologic Products from an “overweight” rating to an “equal weight” rating and set a $84.00 target price on the stock. in a research note on Monday, November 5th.
Large investors have recently modified their holdings of the company. Gabelli Funds LLC acquired a new stake in shares of China Biologic Products in the 3rd quarter valued at $232,000. Fox Run Management L.L.C. acquired a new stake in shares of China Biologic Products in the 3rd quarter valued at $262,000. Myriad Asset Management Ltd. acquired a new stake in shares of China Biologic Products in the 2nd quarter valued at $348,000. Parametrica Management Ltd acquired a new stake in shares of China Biologic Products in the 2nd quarter valued at $386,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in shares of China Biologic Products in the 3rd quarter valued at $352,000. Institutional investors own 44.12% of the company’s stock.
Shares of China Biologic Products stock opened at $69.23 on Wednesday. The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of 16.51, a price-to-earnings-growth ratio of 5.11 and a beta of 1.40. China Biologic Products has a 52-week low of $60.08 and a 52-week high of $107.44.
China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.09 by ($0.13). The business had revenue of $119.10 million during the quarter, compared to the consensus estimate of $122.00 million. China Biologic Products had a net margin of 15.50% and a return on equity of 11.44%. The company’s quarterly revenue was up 19.6% compared to the same quarter last year. During the same period last year, the firm earned $1.32 EPS. On average, equities research analysts forecast that China Biologic Products will post 3.43 earnings per share for the current fiscal year.
About China Biologic Products
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
Read More: Trading Strategy Examples and Plans
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.